Dr. The disease. Presented preliminary data from the Phase 1b study in Novel Therapeutics and Drug Resistance session in an oral presentation entitled ‘# 1070: PX-171-006: Phase IB Multicenter Dose Escalation Study of Carfilzomib and lenalidomide and Low Dose dexamethasone in relapsed and refractory multiple myeloma . Preliminary Results ‘. The median time to disease

Read More